The addition of Cytosorb in patients on VA-ECMO improves urinary output and ICU survival.

IF 1.5 4区医学 Q3 HEMATOLOGY Therapeutic Apheresis and Dialysis Pub Date : 2024-02-01 Epub Date: 2023-09-11 DOI:10.1111/1744-9987.14064

Daniel Lovrić, Marijan Pašalić, Stefan Križanac, Karla Kovačić, Boško Skorić, Hrvoje Jurin, Davor Miličić, Vedran Premužić

{"title":"The addition of Cytosorb in patients on VA-ECMO improves urinary output and ICU survival.","authors":"Daniel Lovrić, Marijan Pašalić, Stefan Križanac, Karla Kovačić, Boško Skorić, Hrvoje Jurin, Davor Miličić, Vedran Premužić","doi":"10.1111/1744-9987.14064","DOIUrl":null,"url":null,"abstract":"Introduction: The aim of this study was to analyze the efficiency of CytoSorb adsorber in patients presenting with cardiogenic shock and treated with venoarterial extracorporeal membrane oxygenation (VA-ECMO).Methods: Sixteen patients put on VA ECMO due to cardiogenic shock were included, stratified according to the use of Cytosorb adsorber in the first 24 h and compared across different clinical outcomes.Results: Significantly lower vasopressor doses were required among patients treated with Cytosorb at the initiation and before weaning from ECMO. Furthermore, these patients showed significantly higher urine output before weaning and lower lactate levels during the extracorporeal support. Finally, the mortality rate was lower among the Cytosorb therapy group (22.2% vs 57.1%).Conclusion: While a decrease in vasopressor doses was already associated with CytoSorb use, this is the first study showing an increase in urinary output and a trend towards better survival among patients on VA ECMO treated with CytoSorb.","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Apheresis and Dialysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1744-9987.14064","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The aim of this study was to analyze the efficiency of CytoSorb adsorber in patients presenting with cardiogenic shock and treated with venoarterial extracorporeal membrane oxygenation (VA-ECMO).

Methods: Sixteen patients put on VA ECMO due to cardiogenic shock were included, stratified according to the use of Cytosorb adsorber in the first 24 h and compared across different clinical outcomes.

Results: Significantly lower vasopressor doses were required among patients treated with Cytosorb at the initiation and before weaning from ECMO. Furthermore, these patients showed significantly higher urine output before weaning and lower lactate levels during the extracorporeal support. Finally, the mortality rate was lower among the Cytosorb therapy group (22.2% vs 57.1%).

Conclusion: While a decrease in vasopressor doses was already associated with CytoSorb use, this is the first study showing an increase in urinary output and a trend towards better survival among patients on VA ECMO treated with CytoSorb.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在使用 VA-ECMO 的患者中添加 Cytosorb，可提高尿量和重症监护室存活率。

简介本研究旨在分析CytoSorb吸附剂在心源性休克并接受静脉体外膜氧合（VA-ECMO）治疗的患者中的应用效果：方法：纳入16例因心源性休克而接受体外膜肺氧合（VA-ECMO）治疗的患者，根据患者在最初24小时内使用Cytosorb吸附剂的情况进行分层，并比较不同的临床结果：结果：在开始使用和从 ECMO 断奶前使用 Cytosorb 吸附剂的患者所需的血管加压剂剂量明显较低。此外，这些患者在断奶前的尿量明显增加，体外支持期间的乳酸水平降低。最后，Cytosorb疗法组的死亡率较低（22.2% 对 57.1%）：结论：虽然使用 CytoSorb 已导致血管加压剂剂量减少，但这是首次有研究显示使用 CytoSorb 治疗的 VA ECMO 患者的尿量增加，存活率也呈上升趋势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutic Apheresis and Dialysis 医学-泌尿学与肾脏学

CiteScore

3.00

自引率

10.50%

发文量

166

审稿时长

6-12 weeks

期刊介绍： Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy. The Journal publishes original articles, editorial comments, review articles, case reports, meeting abstracts and Communications information on apheresis and dialysis technologies and treatments.